Abstract
Introduction Gliomas are the most common primary tumour of the central nervous system (CNS), with an estimated annual incidence of 6.6 per 100,000 individuals in the USA and around 14 deaths per day from brain tumours in the UK. The genomic and biological landscape of brain tumours has been increasingly defined and, since 2016, the WHO classification of tumours of the CNS incorporates molecular data, along with morphology, to define tumour subtypes more accurately. The Tessa Jowell BRAIN MATRIX Platform (TJBM) study aims to create a transformative clinical research infrastructure that leverages UK NHS resources to support research that is patient centric and attractive to both academic and commercial investors.
Methods and analysis The TJBM study is a programme of work with the principal purpose to improve the knowledge of glioma and treatment for glioma patients. The programme includes a platform study and subsequent interventional clinical trials (as separate protocols). The platform study described here is the backbone data-repository of disease, treatment and outcome data from clinical, imaging and pathology data being collected in glioma patients from secondary care hospitals. The primary outcome measure of the platform is time from biopsy to integrated histological-molecular diagnosis using whole genome sequencing and epigenomic classification. Secondary outcome measures include those that are process-centred, patient-centred and framework-based. Target recruitment for the study is 1000 patients with interim analyses at 100 and 500 patients.
Ethics and dissemination The protocol was approved by West Midlands - Edgbaston Research Ethics Committee. Participants will be required to provide written informed consent. The results of this study will be disseminated through national and international presentations and peer-reviewed publications.
Trial registration number ClinicalTrials.gov Identifier: NCT04274283; 18-Feb-2020
ISRCTN 14218060; 03-Feb-2020
Strengths and limitations of this study
The TJBM study is a programme of work, which will improve the knowledge of glioma, and treatment for glioma patients.
This platform study is a backbone data-repository of disease, treatment and outcome data from clinical, imaging and pathology data
The TJBM study will aim to provide rapid and accurate molecular diagnosis, a network of clinical hubs with robust protocols for the collection, processing, analysis and storage of tissue, images, and clinical and quality of life data
Gliomas occur at all ages and their specific subtype is difficult to predict preoperatively, therefore, the patient population eligible for the study is broad but currently excludes <16-year-old patients
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04274283, ISRCTN14218060
Funding Statement
This study was funded by The Brain Tumour Charity (GN-000580) and Genomics England with funding from INNOVATE UK
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of West Midlands - Edgbaston Research Ethics Committee gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Additional Investigators of the BRAIN MATRIX study are listed in Supplementary Appendix 1.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos